Genmab A/S (OTCMKTS:GNMSF – Get Free Report) rose 5.8% during mid-day trading on Friday. The company traded as high as $400.00 and last traded at $400.00. 746 shares changed hands during trading, a decline of 70% from the average session volume of 2,499 shares. The stock had previously closed at $378.00.
Genmab A/S Stock Performance
The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company has a 50 day simple moving average of $348.29 and a 200-day simple moving average of $298.03. The firm has a market cap of $24.37 billion, a PE ratio of 31.04 and a beta of 0.75.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Further Reading
- Five stocks we like better than Genmab A/S
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
- Capital One Earnings: After a Double Beat the Rally Is On
- Tractor Supply’s Q3 Beat Plants the Seeds for a Stock Rebound
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
